Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple SclerosisJeffrey A. Cohen, Ludwig Kappos, Paolo Gallo et al.|New England Journal of Medicine|2010Cited by 2.2k
Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS studyBhupendra Khatri, Jeffrey A. Cohen, Frederik Barkhof et al.|The Lancet Neurology|2011Cited by 216
Long-term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS studyJeffrey A. Cohen, Ludwig Kappos, Bhupendra Khatri et al.|Journal of Neurology Neurosurgery & Psychiatry|2015Cited by 163
Fingolimod versus intramuscular interferon in patient subgroups from TRANSFORMSJeffrey A. Cohen, Gordon Francis, Frederik Barkhof et al.|Journal of Neurology|2013Cited by 88